

Material Information (3176 MEDIGEN)

SEQ_NO	1	Date of announcement	2026/02/10	Time of announcement	17:34:11
Subject	Announcement on Behalf of the Subsidiary, Medic Vision AI Ltd. Regarding the Signing of a New Business MOU				
Date of events	2026/02/10	To which item it meets	paragraph 10		
Statement	<p>1.Date of occurrence of the event:2026/02/10</p> <p>2.Counterparty to the contract or commitment:Centre for Eye Research Australia Limited, Winston Medical Supply Co., Ltd.</p> <p>3.Relationship with the Company:Centre for Eye Research Australia Limited is a non-related party Winston Medical Supply Co., Ltd. is a subsidiary.</p> <p>4.Starting and ending dates (or rescission date) of the contract or commitment:2026/02/10-2028/02/09</p> <p>5.Major content (not applicable where rescinded): The Company hereby announces that its subsidiary, Medic Vision AI Limited (hereinafter referred to as "MVA"), entered into two Memoranda of Understanding ("MOU") today (Feb. 10, 2026), respectively with Centre for Eye Research Australia Limited ("CERA") and the Company's subsidiary Winston Medical Supply Co., Ltd. ("Winston"). Pursuant to the MOU between MVA and CERA, both parties expressed their mutual intention to collaborate in addressing Inherited Retinal Diseases (IRD) by leveraging gene therapy, artificial intelligence, and related ophthalmic technologies to advance IRD treatments development and commercialization. The collaboration may include the establishment of a joint venture company to implement commercialization. Under the MOU between MVA and Winston, both parties expressed their intention to collaborate on the development and commercialization of ophthalmic pharmaceutical products in Australia, New Zealand, and Southeast Asia markets. Winston will provide product supply as well as relevant regulatory and technical support, while MVA will focus on market evaluation, regulatory and commercialization activities.</p> <p>6.Restrictive covenants (not applicable where rescinded):none</p> <p>7.Commitment (not applicable where rescinded):none</p> <p>8.Any other important agreement (not applicable where rescinded):none</p> <p>9.Effect on company finances and business:The term sheet for the proposed joint venture merely sets forth the intentions and mutual understanding of the parties and, as of the date hereof, has not had any material impact on the subsidiary's financial position or business operations.</p> <p>10.Concrete purpose/objective:To build a strategic alliance and thereby strengthen the subsidiary's strategic positioning in the ophthalmic pharmaceutical field.</p> <p>11.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 8 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): The development of new drugs takes a long time, involves high investment costs and there is no guarantee of success. This may expose investment to risks and investors should exercise due diligence and invest with caution.</p>				